Retinoblastoma (RB) is a malignant intraocular
neoplasm that occurs in children. Diagnosis and
therapy are frequently delayed, often leading to
metastasis, which necessitates effective imaging and treatment. In recent years, the use of nanoplatforms allowing both imaging and targeted treatment has attracted much attention. Herein, we report a novel nanoplatform
folate-receptor (FR) targeted
laser-activatable
liposome termed FA-DOX-ICG-PFP@Lip, which is loaded with
doxorubicin (DOX)/
indocyanine green (ICG) and liquid
perfluoropentane (PFP) for photoacoustic/ultrasound (PA/US) dual-modal imaging-guided chemo/photothermal RB
therapy. The dual-modal imaging capability, photothermal conversion under
laser irradiation, biocompatibility, and antitumor ability of these
liposomes were appraised. The multifunctional
liposome showed a good
tumor targeting ability and was efficacious as a dual-modality
contrast agent both in vivo and in vitro. When
laser-irradiated, the
liposome converted light energy to heat. This action caused immediate destruction of
tumor cells, while simultaneously initiating PFP phase transformation to release DOX, resulting in both photothermal and chemotherapeutic antitumor effects. Notably, the FA-DOX-ICG-PFP@Lip showed good biocompatibility and no systemic toxicity was observed after
laser irradiation in RB
tumor-bearing mice. Hence, the FA-DOX-ICG-PFP@Lip shows great promise for dual-modal imaging-guided chemo/
photothermal therapy, and may have significant value for diagnosing and treating RB.